- In April 2023, Thermo Fisher Scientific Inc., a major player in the pharmacogenomics landscape, announced the expansion of its production facility in South Africa, targeting increased regional access to genomic testing. This strategic initiative is expected to strengthen pharmacogenomic infrastructure across emerging markets and contributed 2.8% to the company’s global revenue in the genomics division. The expansion supports local healthcare providers with customized genomic solutions and promotes equitable access to precision medicine
- In March 2023, Myriad Genetics, Inc., launched its GeneSight Psychotropic 4.0, an advanced pharmacogenomic test for guiding psychiatric medication decisions. The updated panel offers broader gene coverage and enhanced interpretability for clinicians. Since its release, GeneSight has been adopted by over 8,000 physicians across the U.S., contributing to a 6.1% quarterly increase in the company’s personalized medicine testing revenue
- In March 2023, Illumina Inc. partnered with the Government of India on the "Genomics for Public Health" initiative, aimed at improving pharmacogenomic research and public health policy development. This move is projected to boost Asia-Pacific’s pharmacogenomics sector, which accounted for 25.8% of the global market share in 2024. The initiative includes the deployment of whole-genome sequencing platforms to support pharmacogenetic data integration in national health systems
- In February 2023, 23andMe Holding Co. entered a licensing agreement with GSK to co-develop pharmacogenomic biomarkers for autoimmune drug response. The collaboration focuses on integrating consumer genomic data with clinical trials, streamlining patient stratification. This partnership is expected to accelerate drug development timelines and contributed an estimated 3.5% to the company’s partnership revenue in 2024
- In January 2023, Qiagen N.V. launched its QIAseq Pharmacogenomics Panel, a targeted NGS assay designed for comprehensive pharmacogenetic variant detection across major drug-metabolizing genes. The product supports both clinical research and diagnostic labs. Initial uptake in Europe and North America contributed 4.2% to Qiagen’s revenue growth in its Molecular Diagnostics segment during the first half of 2024
